Cyromazine TC Pharma Grade API, chemically designated N-cyclopropyl-1,3,5-triazine-2,4,6-triamine, CAS 66215-27-8, is supplied as a white to off-white crystalline powder with a molecular weight of 166.19 g/mol, a melting point of 220–222°C, an aqueous solubility of approximately 13 g/L at 20°C, and a calculated log P near -0.06. The compound acts as an insect growth regulator, interfering with dipteran larval moulting by disrupting chitin deposition and cuticle formation rather than exerting acute neurotoxic effects. Downstream pharmaceutical and veterinary formulation chains handling this API most frequently encounter it in low-dose granulated feed premixes, oral solid dosage intermediates, aqueous drench suspensions, and preformulation injectable suspensions. The physicochemical profile creates distinct processing constraints: the relatively high aqueous solubility for a triazine derivative permits aqueous suspension manufacturing without cosolvent saturation, while the low log P, compacted crystal habit, and dose-critical content uniformity requirements generate poor powder flow and segregation risk in direct compression when active loading falls below a formulation-dependent threshold. Each application scenario below provides a production-relevant processing boundary, the applicable compliance framework, the formulation loading window, the manufacturing route, and the terminal product form.

Why Does Low-Dose Cyromazine Require Roller Compacted Granulation in Poultry Feed Premix Lines?

The dominant commercial downstream route for Cyromazine TC Pharma Grade API is the manufacture of medicated feed premix granules for poultry operations, where the active substance is delivered orally at a registered final feed concentration of 5 mg/kg (5 ppm) to suppress manure-breeding flies such as Musca domestica and Fannia canicularis. A 2% w/w commodity premix is dosed at 250 g per tonne of complete feed to deliver the labelled concentration. The production bottleneck in this downstream sector is not chemical instability but mismatched particle size distribution between the active ingredient, typically milled with a volume mean diameter below 75 µm, and feed-grade carrier granules ranging from 400 µm to 850 µm. Direct 1:1,000 dilution without staged geometric blending produces measurable segregation in double ribbon mixer discharge samples, especially when ambient relative humidity drops below 30% and triboelectric charging increases adherence of API particles to mixer walls and flight surfaces. Production-scale field observations from 2,000 kg double ribbon mixers indicate that batch-to-batch variance is minimised when the first pre-blend step is fixed at 1:10 with ground limestone, followed by a second 1:10 dilution into corn cob or wheat middling carrier granules before final feed incorporation.

For a standard 2% w/w cyromazine premix, the manufacturing sequence begins with sieving the API through a 250 µm screen to remove compacted agglomerates. The API is then blended with ground limestone in a double ribbon mixer operating at approximately 80% nominal fill volume for 15 minutes, discharged through a vibratory sifter, and subsequently incorporated into dried corn cob granules in a second blending pass. To stabilise the blend against sifting and dust formation, the final premix is roll compacted at pressures in the range of 4 kN/cm to 8 kN/cm depending on carrier friability, then sieved to a granule size distribution of 150–850 µm. Granules below 150 µm are recycled into the feed stream of the compactor; granules above 850 µm are milled and re-screened. The granulated premix is packed into multi-wall paper bags with polyethylene liners, and exposed storage is avoided at moisture levels above 8% because hygroscopic carrier components cause caking and microdosing failure in volumetric feeders. The finished premix granule is the principal intermediate for mash and pelleted poultry feeds, and the final feed is typically labelled for manure fly larvae control with a zero-day withdrawal period in broilers where national registration supports that claim.

Direct compression of Cyromazine TC Pharma Grade API at loadings below 4% w/w in a 200–250 mg tablet core generates acceptance value failures under USP 905 and Ph. Eur. 2.9.40 when the micronised API contains a D₉₀ above 75 µm and no staged geometric pre-blend is used. In veterinary compounding and small-batch oral solid dose work, the active fraction in compressed tablets is most commonly held between 4% w/w and 25% w/w, corresponding to compounded strengths of 10–50 mg per unit in a 200–250 mg core. Above 25% w/w, the compacted crystalline habit of cyromazine reduces tensile strength and increases capping on rotary tablet presses at standard turret speeds. Below 4% w/w, the principal failure mode is not compressibility but content uniformity, driven by particle size mismatch between API and lactose monohydrate or microcrystalline cellulose carriers. The differentiation between tablet and capsule lines is therefore not the dosage form but the powder-feeding strategy: tablet production tolerates slightly higher active fraction because die fill is assisted by forced feeders, while capsule filling with dosator nozzles requires a more free-flowing blend with stricter particle-size control.

The applicable compliance framework for this downstream segment includes USP 905 and Ph. Eur. 2.9.40 for uniformity of dosage units, USP 1174 for powder flow classification, ICH Q3D (R2) for elemental impurities, and VICH GL18 (R2) for residual solvent control when wet granulation solvents are avoided in favour of direct compression. In a representative small-scale direct compression line, the API is first combined with fumed silica at 0.5% w/w and passed through a 500 µm sieve to reduce triboelectric charging. The pre-blend is added to spray-dried lactose monohydrate, microcrystalline cellulose PH-102, and 3% w/w croscarmellose sodium, then blended in a V-blender at 25 rpm for 20 minutes. Tablets are compressed on a rotary press at 8–14 kN main compression force, with target hardness of 5–8 kp and friability below 1%. Capsule filling on a dosator machine uses the same pre-blend adjusted with additional glidant to maintain flow function suitable for 60–80% nozzle fill. Finished forms are veterinary compounded tablets or hard hydroxypropyl methylcellulose capsules; no harmonised multinational commercial monograph for cyromazine oral solid dosage forms has been identified, and published stability data for this specific configuration are limited.

Aqueous Oral Drench Suspensions for Cyromazine in Species-Specific Veterinary Channels

Aqueous drench suspension manufacturing for Cyromazine TC Pharma Grade API exploits the measured equilibrium solubility near 13 g/L at 20°C, which allows a 10 mg/mL (1% w/v) oral suspension to be formulated without high cosolvent fractions that would create palatability and precipitation problems. The primary formulation challenge in this downstream route is not dissolution but physical stability: cyromazine crystals smaller than 10 µm tend to form hard sediment during storage, while crystals above 30 µm produce rapid settling and inconsistent dose delivery through drench guns. The preferred suspension format therefore uses a pH-adjusted buffered vehicle in the range of pH 4.5–5.5, where the triazine ring remains chemically stable and the hydrated polymer network can maintain a yield stress sufficient to suspend particles without producing excessive viscosity. A production viscosity below 200 mPa·s at 25°C is typically required for reliable passage through standard livestock drench gun orifices at field temperatures below 15°C.

The manufacturing route for a 10 mg/mL oral drench suspension begins with hydration of xanthan gum at 0.2% w/v in a citrate buffer system, followed by slow addition of the API under high-shear rotor-stator mixing at 5,000 rpm for 10 minutes. Polysorbate 80 at 0.1% w/v is introduced before API addition to reduce interfacial aggregation, and sodium benzoate at 0.1% w/v serves as the preservative system. The suspension is deaerated under vacuum to remove foam generated during high-shear mixing, then filled into high-density polyethylene drench pack containers with a headspace below 5% of nominal fill volume. Compliance anchors for this segment include VICH GL18 (R2), ICH Q3C for residual solvents where methanol or isopropanol is used in valve-cleaning steps, Ph. Eur. 2.9.36 for flowability, and applicable current good manufacturing practice under 21 CFR Part 210/211 where the product is registered as a veterinary medicinal product rather than a feed additive. The terminal finished product type is an oral drench suspension for veterinary administration; published data on long-term physical stability of cyromazine in this exact vehicle configuration are limited, and formulators conducting stability programmes should include resuspendability testing over 4°C–40°C cycling.

When a Sterile Injectable Suspension Is Formulated from Cyromazine API

Injectable use of Cyromazine TC Pharma Grade API is not established in commercial veterinary pharmacopoeial monographs, and published data for this specific configuration are limited. Where preformulation units evaluate a sterile suspension, the target concentration is typically 50 mg/mL in water for injection, using 0.5% w/v sodium carboxymethylcellulose as suspending agent and 0.1% w/v polysorbate 80 as wetting agent. The pH is adjusted to 5.0 ± 0.5, because higher pH values above 6.0 can shift the aqueous solubility profile and promote Ostwald ripening in submicron particle distributions. The critical process parameter in this downstream segment is not chemical degradation under terminal sterilisation but particle growth during autoclaving: uncontrolled high-polymer hydration during the 121°C heating phase can increase mean particle diameter beyond the 20 µm D₉₀ threshold specified for injectable suspension syringability through 21-gauge needles. Production routes therefore use high-shear homogenisation at 10,000 rpm for 15 minutes before autoclave loading, followed by low-speed paddle agitation during the sterilisation hold to prevent sedimentation and polymer gel stratification.

The compliance framework for investigational sterile cyromazine suspension work includes Ph. Eur. 5.1.1 for sterility, Ph. Eur. 5.1.4 for bacterial endotoxins, 21 CFR Part 210/211 where the batch is manufactured under drug GMP, and ICH Q3D (R2) for elemental impurities. Terminal sterilisation at 121°C for 15 minutes is the default cycle; filter sterilisation is not applicable to suspension dosage forms. Post-autoclave particle size is measured by laser diffraction, and viscosity is retested after cooling to 25°C because sodium carboxymethylcellulose exhibits thermal thinning during the sterilisation plateau. The terminal product form is a sterile injectable suspension for investigational veterinary use only; formulators should document that no marketed injectable monograph for cyromazine has been identified in the target jurisdiction, and should not substitute this preformulation rationale for registration data.

A granulated cyromazine premix for automated microdosing systems in poultry feed mills is manufactured using a continuous ribbon mixer and fluid-bed dryer line, a distinct downstream segment from bag-mixed on-farm premixes because the granule must remain free-flowing at very low dose rates without sifting in vertical feed delivery lines. The active content is standardised at 2% w/w, and the microdosing system is set to deliver 250 g premix per tonne of final feed to reach the target 5 mg/kg feed concentration. The granulation route uses corn starch binder at 5% w/w on dry solids in a high-shear granulator, followed by fluid-bed drying at an inlet air temperature of 60°C until loss on drying is below 2.5%. The dried granules are screened to 300–1,000 µm; the 300 µm lower cut is critical because dusty fines below that size accumulate in microdosing auger clearances and produce inaccurate deliveries of ±10% or more. The finished granules are packed in 25 kg bags with antistatic polyethylene liners, and the production area is maintained at 40–60% relative humidity to prevent electrostatic adhesion of cyromazine powder to metal dosing hoppers. Compliance anchors for this segment include 21 CFR 507 for animal food preventive controls, GMP+ BA2 for feed safety assurance, and ISO 22000 where the feed mill operates an integrated food safety management system. The terminal product type is a dust-free microdosing granule for automated poultry feed mill application, not a finished feed.

Capsule Powder Blending of Cyromazine Requires Glidant-Assisted Pre-Blending and Strict Relative Humidity Control

Capsule filling of Cyromazine TC Pharma Grade API differs from tablet compression in one critical respect: the powder blend must flow through a dosator or tamping pin head without forced die fill assistance, so the acceptable active fraction in the final blend is lower than in tablet manufacture unless a granulation step is introduced. For strengths below 25 mg per capsule in a 400–500 mg fill, the active fraction is commonly held under 5% w/w; above 50 mg per capsule, direct filling without roller compaction frequently fails the flow index thresholds described in USP 1174 because cyromazine crystals are irregularly compacted and resist free gravitational discharge. The use of fumed silica at 0.25–0.5% w/w as a glidant-assisted pre-blend is mandatory when ambient relative humidity cannot be held below 50%; without this step, the powder blend develops triboelectric coatings on stainless steel dosator pins and produces weight variation outside the acceptance limits of USP 905 and Ph. Eur. 2.9.40.

The processing sequence for a hard hydroxypropyl methylcellulose capsule batch begins with combining the API and fumed silica in a bin blender at 12 rpm for 15 minutes, then passing the pre-blend through a 500 µm screen to break electrostatic agglomerates. The pre-blend is then incorporated into a base of spray-dried lactose monohydrate and pregelatinised starch, with 0.5% w/w magnesium stearate added in the final 3 minutes of blending to limit over-lubrication. Capsule filling on a dosator machine is conducted at 60–80% nominal fill volume with relative humidity maintained between 30% and 50%; RH above 60% causes moisture uptake in pregelatinised starch and increases powder adhesion. The terminal finished product type is a hard hydroxypropyl methylcellulose capsule for veterinary oral administration; published data for long-term dissolution testing of cyromazine from HPMC capsules are limited, and the lack of a harmonised compendial dissolution method means that formulators typically rely on disintegration testing under Ph. Eur. 2.9.1 during development batches.